N. Maheshwary, “EFFICACY AND COST EFFECTIVENESS OF BIOSIMILAR PEGYLATED INTERFERON α2a 180 µg/RIBAVIRIN IN NON-CIRRHOTIC TREATMENT NAÏVE GENOTYPE 3 PATIENTS”, Pak J Phsyiol, vol. 12, no. 1, pp. 26–28, Mar. 2016.